NYP/Weill Cornell physician-scientists present latest cancer findings at ASCO meeting
...y, M. J. Morris, S. Vallabhajosula, S. Goldsmith, D. Matulich, J. Kaplan, F. Berger, H. I. Scher, N. H. Bander, D. M. Nanus
Drs. Scott Tagawa, Neil bander
and their colleagues at NewYork-Presbyterian/Weill Cornell will present data from a Phase II clinical trial showing that a monoclonal antibody designa...
J591- an Antibody Exclusively Targets Tumors
...pies aimed directly at the malignant cells, along with therapies to both directly kill the tumor's blood supply as well as prevent it from regrowing," bander
said. Source-Eurekalert PRI ...
First Treatment to Directly Target Tumor Blood Supply
"We showed that J591 can directly target the tumor's blood vessels," Dr. bander
says. "That's an important first. It represents the difference between layi...small trial did not turn up significant reductions in tumor volume, but Dr. bander
says the trial wasn't designed to do so.
"This was a proof-of-princi...
Nanomedicine research for prostate cancer supported by $5 million gift
...atients and have demonstrated sensitive and specific cancer targeting in 97 percent of prostate cancer patients as well as anti-tumor activity.
is the inventor on patents that are owned by Cornell Research Foundation ("CRF") for the antibody technology described in this release. He is a paid c...